Novogenia

Novogenia is an Austrian biotechnology and personalized-health company founded in 2009 and headquartered in the Salzburg region, with its modern laboratory and production facility in Eugendorf. It describes itself as one of the very few companies in Europe that owns every step of the value chain: a customer sends in a single saliva sample, Novogenia analyzes the DNA in its own EU laboratory, and then turns the result into finished personalized products — micro-dosed supplements formulated to a person's genetic profile and BeautyMe personalized cosmetics formulated to the skin's genetic needs. The company positions this as "one platform — from a single saliva sample to a finished, personalized product. All under one roof." The operating business is Novogenia GmbH, the flagship laboratory and production subsidiary of the stock-listed parent Novogenia AG. Novogenia AG is the listed holding company (ISIN DE000A3C35W0), traded on XETRA and the Munich Stock Exchange, and it groups the operating subsidiaries and strategic investments into business segments spanning diagnostics and personalized products, personalized therapies (including personalized infusion therapies and IVF / reproductive genetics), and related pharmaceutical and medical-device activities. The group reports a roughly 4,000 m² lab and production facility, around 250 employees, and more than 275,000 people analyzed, and it states it has been profitable since 2013. Novogenia's consumer-facing offer centers on at-home DNA testing: a saliva sample is analyzed in the company's own EU laboratory and returned as clear, personalized reports covering areas such as nutrition, weight, ageing, disease risk and athletic potential. Those reports then feed the group's product lines — personalized supplements (vitamins, minerals and actives micro-dosed to the genetic profile, produced in Austria) and personalized cosmetics under the BeautyMe brand (serums and body lotion developed and produced entirely in-house). The company also sells a book by founder and CEO Dr. Daniel Wallerstorfer, PhD, titled "Unlock Your Genes for Precision Health." Beyond consumer genetics, Novogenia serves businesses of all sizes, developing and manufacturing analytical methods and personalized products for partners, and it operates subsidiaries covering sales to doctors (NovoMedic GmbH), sales to pharmacies (GENius GmbH), clinical genetics (HLN Genetik GmbH), software and bioinformatics (Mendelio Srl), B2C cosmetics (305Care GmbH), group marketing and real estate, and pharmaceutical import and medical devices in Germany. The group's stated mission is to empower people to take charge of their health and well-being using personalized analyses and products based on their individual genetic and biological data, and its vision is to become the leading provider of personalized products and services based on individual biological data — first in Europe, then worldwide. Its stated operating principle is "Analyse. Learn. Solve. Explore."

Novogenia was founded in Austria in 2009, at a time when consumer genetics was still an emerging field. From the outset the company focused on the potential of genetics as the foundation for personalized supplements, cosmetics and analytical methods, rather than on genetic testing alone. Its founder and CEO, Dr. Daniel Wallerstorfer, a molecular biologist and biotechnologist, built the business around the idea that a person's DNA could be read and then put to practical use in everyday health, nutrition and care. Over the following years Novogenia grew from a genetics laboratory into an integrated developer and manufacturer. It established its own laboratory and production facility in Eugendorf in the Salzburg region of Austria — today described as a roughly 4,000 m² lab and production facility — and expanded its team to around 250 employees. The company reports that it has been profitable since 2013, and that it has analyzed more than 275,000 people. It holds ISO 9001, ISO 22000 and ISO 22176 certifications, a medical genetics license and CLIA accreditation, and it markets itself as a European market leader in its field. A defining strategic choice was vertical integration. Rather than outsourcing analysis or manufacturing, Novogenia kept the entire chain in-house: a saliva sample arrives from the customer, is analyzed in the company's own EU laboratory, and the resulting data is turned into finished personalized products — supplements micro-dosed to the genetic profile and produced in Austria, and BeautyMe cosmetics formulated to the skin's genetic needs and developed and produced entirely in-house. The company summarizes this as "one platform — from a single saliva sample to a finished, personalized product. All under one roof," and notes that because of this integration the sample never has to leave the building, let alone the EU. To organize its expanding activities, the group created a stock-listed parent, Novogenia AG, which is the listed holding company (ISIN DE000A3C35W0) traded on XETRA and the Munich Stock Exchange. Novogenia GmbH remains the flagship laboratory and production subsidiary, fully consolidated under the parent. Around it the group has assembled a portfolio of operating subsidiaries and strategic investments, grouped into business segments. These include NovoMedic GmbH (sales to doctors, Eugendorf), GENius GmbH (sales to pharmacies, Eugendorf), 305Care GmbH (B2C cosmetics, Germany), HLN Genetik GmbH (clinical genetics laboratory, Austria), Mendelio Srl (software and bioinformatics, Romania), Novogenia Marketing GmbH (group marketing, Eugendorf) and Darwin Immobilien GmbH (group real estate, Austria). In Germany, Darwin Pharma Holding GmbH (Munich) holds pharmaceutical and medical-device businesses including INOPHA GmbH (drug import and distribution), ChiruTec GmbH (medical devices) and Medicopharm AG (pharmaceutical import). The group also holds minority financial investments in REVIV (IV-therapy and wellness clinics, United Kingdom), GenePlanet (consumer genetics, Ljubljana, Slovenia), Spot Health Inc. (digital health, USA) and GenomeLink (DNA-app platform, USA), and wholly owns Nephrogen Inc. (gene therapy, USA). The group's business segments span diagnostics and personalized products, personalized therapies — including personalized infusion therapies and IVF / reproductive genetics — and the pharmaceutical and medical-device activities described above. Novogenia AG states that it harnesses advances in biotechnology and artificial intelligence to create highly personalized solutions from scientific lab-analysis data, and it describes a feedback loop of "analyse → product → re-analyse." Its stated mission is to empower people to take charge of their health and well-being with personalized analyses and products based on their individual genetic and biological data; its vision is to become the leading provider of personalized products and services based on individual biological data, first in Europe and then worldwide. The company's operating principle is summarized as "Analyse. Learn. Solve. Explore."

• 2013

  Company reports it has been profitable since 2013.

• 2009

  Novogenia founded in Austria, focused on the potential of genetics for personalized supplements, cosmetics and analytical methods.

• Novogenia AG established as the stock-listed parent holding company, traded on XETRA and the Munich Stock Exchange (ISIN DE000A3C35W0).

• Group reports more than 275,000 people analyzed and a roughly 4,000 m² lab and production facility with around 250 employees.

• Group reports cumulative revenue of approximately €500 million since 2009 and a new headquarters and laboratory.

One of the few European companies owning the entire chain from DNA analysis to finished personalized product — "one platform, all under one roof" — combining an EU laboratory, in-house supplement and cosmetics manufacturing, and AI-assisted interpretation of genetic data.

• Genetic analysis (saliva sample)

  A saliva sample from home, analyzed in Novogenia's own EU laboratory and turned into clear, personalized reports — the foundation for everything else.

• Personalized supplements

  Vitamins, minerals and actives, micro-dosed to the genetic profile — produced in the company's own facility in Austria.

• BeautyMe personalized cosmetics

  Serums and body lotion formulated to the skin's genetic needs — developed and produced entirely in-house.

• Book: Unlock Your Genes for Precision Health

  A book by Dr. Daniel Wallerstorfer, PhD, decoding DNA for nutrition, weight, ageing, disease risk and athletic potential; sold in the company's shop.

1. 1Novogenia — Unlock Your Genes for Precision Healthnovogenia.com
2. 2About Us | Novogenianovogenia.com
3. 3Novogenia AG — Group, technologies & investor relationsnovogenia.com
4. 4Brands & Companies — Novogenia AG Investor Relationsnovogenia.com